Breaking News
December 14, 2018 - Lack of peds preventive care ups unplanned hospital admissions
December 14, 2018 - Miscarriage: When Language Deepens Pain
December 14, 2018 - New method helps better understand pathological development of ALS
December 14, 2018 - Intellectually active lifestyle confers protection against neurodegeneration in Huntington’s patients
December 14, 2018 - Mammalian collagen nanofibrils become stronger and tougher with exercise
December 14, 2018 - Considerable Morbidity, Mortality Due to Animal Encounters
December 14, 2018 - Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease
December 14, 2018 - How early physical therapy can lessen the long-term need for opioids
December 14, 2018 - Depression, suicide rates highest in Mountain West states
December 14, 2018 - New model could cure the potential to underestimate how quickly diseases spread
December 14, 2018 - Exercise-induced hormone activates cells critical for bone remodeling in mice
December 14, 2018 - Researchers discover new mechanism behind spread of malignant pleural mesothelioma
December 14, 2018 - Health Tip: Celebrate a Healthier Holiday
December 14, 2018 - Scalpel-free surgery enhances quality of life for Parkinson’s patients, study finds
December 14, 2018 - Early physical therapy can reduce risk, amount of long-term opioid use | News Center
December 14, 2018 - Genetic marker, predictor of early relapse in common childhood cancer discovered
December 14, 2018 - Study could lead to a potential new way of treating sepsis
December 14, 2018 - New protein complex helps embryonic stem cells to maintain their indefinite potential
December 14, 2018 - Salk professor receives $1.8 million from NOMIS Foundation for research on mechanisms to promote health
December 14, 2018 - New discovery will improve the safety and predictability of CRISPR
December 14, 2018 - Geneticists discover how sex-linked disorders arise
December 14, 2018 - New method to visualize small-molecule interactions inside cells
December 14, 2018 - Study describes mechanism that makes people more vulnerable to hunger-causing stimuli
December 14, 2018 - Chronic opioid therapy associated with increased healthcare spending and hospital stays
December 14, 2018 - Blood Types
December 14, 2018 - Obesity linked to increased risk of early-onset colorectal cancer
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
December 14, 2018 - Scientists use water to track electrical activity of nerve cells
December 14, 2018 - Recurrence of urinary tract infection may depend on bacterial strain, study shows
December 14, 2018 - GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 14, 2018 - Partial Thromboplastin Time (PTT) Test: MedlinePlus Lab Test Information
December 14, 2018 - Common tactics for health promotion at work may be detrimental to employees with obesity
December 14, 2018 - Myths about migration and health not supported by available evidence
December 14, 2018 - Recent findings on rare genetic disorder may help develop new treatment options
December 14, 2018 - New drug shows promise in treating sarcomas
December 14, 2018 - Scientists perform lung lavage as new approach for tuberculosis diagnosis in rhinoceros
December 14, 2018 - Recent winners of the Nobel Medicine Prize
December 14, 2018 - KHN’s ‘What the Health?’ Insurance enrollment is lagging — and there are lots of reasons why
December 14, 2018 - Study assesses safety and efficacy of new treatment for pancreatic cancer
December 14, 2018 - Weakened metabolism of immune T cells may account for serious complications in elderly
December 14, 2018 - Study finds drug targets for Ebola, Dengue, and Zika viruses
December 14, 2018 - Face masks may offer protection against staph bacteria for hog farm workers and their household members
December 14, 2018 - Shining new light on neuron firing
December 14, 2018 - Study highlights need for personalized approach to treat ICU acquired delirium
December 14, 2018 - Soot particles from road traffic significantly contribute to air pollution
December 14, 2018 - Massage helps relieve pain, improve mobility in patients with knee osteoarthritis
December 14, 2018 - Researchers explore home healthcare nurses’ knowledge attitudes toward infection control
December 14, 2018 - Average outpatient visit in the U.S. costs nearly $500, shows new study
December 14, 2018 - Reference Infliximab, Biosimilar Equivalent for Crohn’s Disease
December 14, 2018 - New contact lens to treat eye injuries
December 14, 2018 - Acne could have a genetic basis find researchers promising new cure
December 14, 2018 - Higher physical activity associated with improved mood
December 14, 2018 - New UGA study points to optimal hypertension treatment for stroke patients
December 14, 2018 - Study highlights factors that can reduce food cravings
December 14, 2018 - Researchers discover Ebola-fighting protein in human cells
December 14, 2018 - Fentanyl surpasses heroin in cause of U.S. drug overdose deaths
December 14, 2018 - When Heart Attack Strikes, Women Often Hesitate to Call for Help
December 14, 2018 - A warning about costume contacts
December 14, 2018 - Study examines link between peripheral artery disease and heart attack
December 14, 2018 - Researchers develop biotechnological tool to produce antifungal proteins in plants
December 14, 2018 - 3D-printed adaptive aids can benefit patients with arthritis
December 14, 2018 - Chronic bullying during adolescence impacts mental health
December 14, 2018 - Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics
December 13, 2018 - Importance of cell cycle and cellular senescence in the placenta discovered
December 13, 2018 - Gold “nanoprisms” open new window into vessels and single cells
December 13, 2018 - Research findings could lead to new targets for cancer-fighting therapeutics
December 13, 2018 - Butantan Institute signs collaboration agreement with MSD to develop dengue vaccines
December 13, 2018 - Study explores how patients want to discuss symptoms with doctors
December 13, 2018 - RUDN medics first to gather scattered data on hepatitis morbidity in Somalia
December 13, 2018 - Age and gender disparities found in use of bed nets to prevent malaria in sub-Saharan Africa
December 13, 2018 - Caffeine therapy benefits developing brains of premature babies
December 13, 2018 - New review focuses on electrospinning techniques used in musculoskeletal tissue engineering
December 13, 2018 - A new division focused on human immune system
December 13, 2018 - Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla (ZX008) in Dravet Syndrome
December 13, 2018 - BCR ABL Genetic Test: MedlinePlus Lab Test Information
December 13, 2018 - Caffeinated beverages during pregnancy linked to lower birth weight babies
December 13, 2018 - Stanford Medicine Health Trends Report examines opportunity to democratize health care
December 13, 2018 - Obsessive-compulsive disorder may protect individuals from obesity
December 13, 2018 - Scientists investigate how a painful event is processed in the brain
December 13, 2018 - Genetic study reveals new insights into underlying causes of moderate-to-severe asthma
T-CALM Phase 2 clinical study results offer hope for essential tremor patients

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

image_pdfDownload PDFimage_print

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor. The company plans to present results from this proof-of-concept study as a late-breaking poster on Monday, October 8 at the International Congress of Parkinson’s Disease and Movement Disorders® in Hong Kong.

Multiple secondary and exploratory endpoints collectively showed that treatment with CX-8998 10mg twice daily resulted in statistically significant improvement versus placebo in activities of daily living and patient-reported and clinical outcome measures, despite the study’s primary endpoint being missed. In the study, CX-8998 demonstrated a favorable safety and tolerability profile, with patients in the drug treatment arm reporting higher levels of satisfaction with tremor control medication compared to patients on placebo.

“After decades without new effective drug therapy options, we believe that the neurostabilizing effects of CX-8998 provide hope for essential tremor patients,” said Spyros Papapetropoulos, MD, PhD, Cavion’s Executive Vice President of Research & Development and Chief Medical Officer. “The data are particularly compelling given that about two-thirds of patients in the study were on standard of care treatment and significant improvement was achieved with CX-8998 on several measures in a study lasting just one month.”

“Essential tremor is a challenge to treat, and patients often do not respond favorably to the existing medications, many of which have been available for decades,” said Karl Kieburtz, MD, MPH, Professor of Neurology at the University of Rochester Medical Center. “Cavion’s CX-8998 has a novel mechanism of action that may provide substantive improvement, and it could be an important therapeutic contribution above and beyond what we currently have for essential tremor. I look forward to its clinical progress and further investigation. Better medications are needed to treat this common and disabling movement disorder.”

T-CALM was a 28-day, double-blind, placebo-controlled Phase 2 proof-of-concept clinical trial in 95 patients with moderate to severe essential tremor, conducted at 25 sites across the United States. Patients were randomized to receive either placebo or CX-8998 titrated up to 10mg dosed twice daily (BID). A majority of subjects (64 percent) added study drug to their existing standard of care anti-tremor medication.

The primary study endpoint using remote video rating of the Tremor Research Group Essential Tremor Rating Assessment Scale – Performance Subscale (TETRAS-PS), a measure of tremor severity, did not meet significance at Day 28 (p=0.696). In contrast, the same TETRAS-PS scale rated by the study investigators who observed the patients in person resulted in a significant improvement in tremor severity at Day 28 for the CX-8998 treated group compared to placebo (p=0.027). Independent analysis of the video rating process uncovered unexpected complications in implementation. Cavion is working closely with the scientific community to enhance central video rating for use in interventional studies.

Multiple secondary and exploratory endpoints collectively showed statistical significance, with benefits after 28 days of treatment in patients receiving CX-8998 10mg twice daily (BID) compared to placebo in the following scales:

  • The TETRAS Activities of Daily Living (TETRAS-ADL) scale, a measure of tremor impact on daily activities (p=0.049)
  • The Clinician Global Impression of Improvement (CGI-I), a measurement of physician-reported global improvement (p=0.001)
  • The TETRAS Total Score (TETRAS ADL + TETRAS-PS rated by the study Investigators, p=0.029)
  • The Goal Attainment Scale (GAS), a measure of progress toward patient-selected goals (such as dressing oneself, writing a sentence, or drinking out of a cup) (p=0.034)

In addition, the Patient Global Impression of Change (PGI-C), a measure of patient-reported improvement, trended towards significance favoring CX-8998 (p=0.089). Kinesia One, an algorithm-based digital measure developed for Parkinson’s disease, failed to detect a treatment difference in Essential Tremor patients. Additional analyses, including patient satisfaction with control by anti-tremor medication and traditional and digital spirography, support a treatment benefit with CX-8998. The drug showed a favorable safety and tolerability profile, with the majority of adverse events mild to moderate, transient and non-recurring. No major differences between CX-8998 and placebo were observed in laboratory values, vital signs or electrocardiography.

In addition to the T-CALM study for essential tremor, CX-8998 is currently being studied in T-WAVE, a multi-center Phase 2 clinical trial for generalized epilepsy with absence seizures. “The body of evidence supporting our ground-breaking approach is rapidly expanding,” said Andrew Krouse, President and CEO of Cavion. “Our pipeline of T-type calcium channel therapies extends beyond tremor to other neurological diseases that share a common pathophysiology. We look forward to initiating a Phase 3 study in tremor soon.”​

Source:

http://www.cavionpharma.com/

Tagged with:

About author

Related Articles